MedDataX Logo

The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients

NCT ID: NCT00718926

Last Updated: 2008-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dry eye disease is related with oxidative stress at the ocular surface. GSH is one of the key factor of protect from oxidative stress. To evaluate thiol status of ocular surface cells by monitoring GSH concentration, we can evaluate the severity of dry eye.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The conjunctival cells are collected by impression cytology. Those cells are stained with 100 mM of monochlorobimane (MCB, M-1381, Molecular Probes, Eugene, OR) and propidium iodide (PI). Fluorescent intensity, reflecting the amount of icGSH, was inspected under a confocal laser scan microscope. To detect the GSH levels we used a fluorescent MCB probe with excitation and emission wavelengths of 405 nm and 410-480 nm, respectively. The cell-permeating MCB probe is non-fluorescent but forms a fluorescent adduct with GSH in a reaction catalyzed by glutathione-S-transferase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

dry eye Thiol redox Oxidative stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sjogren

Sjogren syndrome with dry eye

No interventions assigned to this group

non-Sjogren

dry eye without Sjogren syndrome

No interventions assigned to this group

Short-BUT

Dry eye by shortened tear break up time

No interventions assigned to this group

control

normal patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* dry eye patients
* control volunteers

Exclusion Criteria

* Young (less than 20) patients
* The patients who rejected this study
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kyoto Prefectural University of Medicine

OTHER

Sponsor Role collaborator

Meiji University of Oriental Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Meiji University of Oriental Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kyoto Prefectural University of Medicine hospital

Kyoto, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jun Yamada, MD, PhD.

Role: CONTACT

Phone: +81-75-251-5663

Email: [email protected]

Norihiko Yokoi, MD, PhD.

Role: CONTACT

Phone: +81-75-251-5663

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shigeru Kinoshita, MD, PhD.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C244

Identifier Type: -

Identifier Source: org_study_id